DGIdb - ALOX5 Gene Record

ALOX5 240 Druggable Genome

Alternate Names:

240
ARACHIDONATE 5-LIPOXYGENASE
ALOX5
5-LO
5-LOX
5LPG
LOG5
152390
435
ENSG00000012779
OTTHUMG00000018081
BE0000248
P09917
ARACHIDONATE 5-LIPOXYGENASE (EC 1.13.11.34) (5-LIPOXYGENASE) (5-LO). [SOURCE:UNIPROT/SWISSPROT;ACC:P09917]
5-lipoxygenase
1385
LOX5_HUMAN
PA46
T00140

Gene Info:

Human Readable Name	DRUGGABLE GENOME
Target Class	Enzymes
Target Subclass	EC:1.13.11.34
Interpro Acc	IPR000907
Interpro Name	Lipoxygenase
Uniprot Status	Swiss-Prot
Interpro Short Name	LipOase
Interpro Type	Family
Uniprot Evidence	1: Evidence at protein level
Target Main Class	Enzymes
Target Subclass	1.13.11.34
Gene Biotype	PROTEIN_CODING
GuideToPharmacology Gene Category Name	Lipoxygenases
GuideToPharmacology Gene Category ID	271

(9 More Sources)

Gene Categories: Category Details

DRUGGABLE GENOME
ENZYME

Publications:

Chen et al., 2002, TTD: Therapeutic Target Database., Nucleic Acids Res.
Allgayer et al., 1984, Soybean lipoxygenase inhibition: studies with the sulphasalazine metabolites N-acetylaminosalicylic acid, 5-aminosalicylic acid and sulphapyridine., Eur. J. Clin. Pharmacol.
Nielsen et al., 1987, Inhibition of 5-lipoxygenase pathway of arachidonic acid metabolism in human neutrophils by sulfasalazine and 5-aminosalicylic acid., Dig. Dis. Sci.
Sircar et al., 1983, Inhibition of soybean lipoxygenase by sulfasalazine and 5-aminosalicylic acid: a possible mode of action in ulcerative colitis., Biochem. Pharmacol.
Wisastra R et al., 2013, Discovery of a novel activator of 5-lipoxygenase from an anacardic acid derived compound collection., Bioorg Med Chem
Yamashita et al., 2000, Inhibition by troglitazone of the antigen-induced production of leukotrienes in immunoglobulin E-sensitized RBL-2H3 cells., Br. J. Pharmacol.
Wenzel, Leukotriene receptor antagonists and related compounds., Can. Respir. J.
Qian et al., 2001, Anti-inflammatory activities of LDP-392, a dual PAF receptor antagonist and 5-lipoxygenase inhibitor., Pharmacol. Res.
Coffey et al., 2001, Peroxynitrite-induced nitrotyrosination of proteins is blocked by direct 5-lipoxygenase inhibitor zileuton., J. Pharmacol. Exp. Ther.
Hardy et al., 1999, Prostaglandins and leukotriene B4 are potent inhibitors of 11beta-hydroxysteroid dehydrogenase type 2 activity in human choriocarcinoma JEG-3 cells., Biol. Reprod.
Wenzel et al., Zileuton: the first 5-lipoxygenase inhibitor for the treatment of asthma., Ann Pharmacother
Guidot et al., 1994, Intrinsic 5-lipoxygenase activity is required for neutrophil responsivity., Proc. Natl. Acad. Sci. U.S.A.
Berger et al., 2007, Zileuton: clinical implications of 5-Lipoxygenase inhibition in severe airway disease., Int. J. Clin. Pract.
Zouboulis et al., 2010, Zileuton prevents the activation of the leukotriene pathway and reduces sebaceous lipogenesis., Exp. Dermatol.
Zouboulis, 2009, Zileuton, a new efficient and safe systemic anti-acne drug., Dermatoendocrinol
Vicente et al., 2001, Modulation of haem oxygenase-1 expression by nitric oxide and leukotrienes in zymosan-activated macrophages., Br. J. Pharmacol.
Pergola C et al., 2014, Indirubin core structure of glycogen synthase kinase-3 inhibitors as novel chemotype for intervention with 5-lipoxygenase., J Med Chem
Karg EM et al., 2009, Structural optimization and biological evaluation of 2-substituted 5-hydroxyindole-3-carboxylates as potent inhibitors of human 5-lipoxygenase., J Med Chem
Schieferdecker S et al., 2015, Myxochelins target human 5-lipoxygenase., J Nat Prod
Taccone-Gallucci et al., 2006, N-3 PUFAs reduce oxidative stress in ESRD patients on maintenance HD by inhibiting 5-lipoxygenase activity., Kidney Int.
Zunić et al., Inhibition of leukotriene formation by diethylcarbamazine modifies the acid-base balance in the rabbits with blast injuries of the lungs., Vojnosanit Pregl
Gross et al., 1991, Effects of some nonsteroidal anti-inflammatory agents on experimental radiation pneumonitis., Radiat. Res.
Bach et al., 1986, Inhibition of the leukotriene synthetase of rat basophil leukemia cells by diethylcarbamazine, and synergism between diethylcarbamazine and piriprost, a 5-lipoxygenase inhibitor., Biochem. Pharmacol.
Davidson et al., 1992, Prolonged pulmonary hypertension caused by platelet-activating factor and leukotriene C4 in the rat lung., J. Appl. Physiol.
Cernak et al., 1996, Leukotrienes in the pathogenesis of pulmonary blast injury., J Trauma
Ramires et al., 2004, Novel inhibitory effect on 5-lipoxygenase activity by the anti-asthma drug montelukast., Biochem. Biophys. Res. Commun.
Vidal et al., 2007, Licofelone, a balanced inhibitor of cyclooxygenase and 5-lipoxygenase, reduces inflammation in a rabbit model of atherosclerosis., J. Pharmacol. Exp. Ther.
Armstrong MM et al., 2014, Inhibitory and mechanistic investigations of oxo-lipids with human lipoxygenase isozymes., Bioorg Med Chem
Ribeiro D et al., 2014, Inhibition of LOX by flavonoids: a structure-activity relationship study., Eur J Med Chem
Chu et al., 2007, Minocycline inhibits 5-lipoxygenase activation and brain inflammation after focal cerebral ischemia in rats., Acta Pharmacol. Sin.
Song et al., 2006, Minocycline protects PC12 cells against NMDA-induced injury via inhibiting 5-lipoxygenase activation., Brain Res.
Song et al., 2004, Minocycline protects PC12 cells from ischemic-like injury and inhibits 5-lipoxygenase activation., Neuroreport
Yu et al., 1992, Inhibition of canine tracheal smooth muscle by mediators from cultured bronchial epithelial cells., Am. J. Physiol.
Boctor et al., 1986, Meclofenamate sodium is an inhibitor of both the 5-lipoxygenase and cyclooxygenase pathways of the arachidonic acid cascade in vitro., Prostaglandins Leukot Med
Manev et al., 1999, Primary cultures of rat cerebellar granule cells as a model to study neuronal 5-lipoxygenase and FLAP gene expression., Ann. N. Y. Acad. Sci.
Rask-Madsen et al., 1992, 5-Lipoxygenase inhibitors for the treatment of inflammatory bowel disease., Agents Actions
Wiggins et al., 2009, Balsalazide: a novel 5-aminosalicylate prodrug for the treatment of active ulcerative colitis., Expert Opin Drug Metab Toxicol
Hawkes et al., 1994, The effect of methotrexate on ex vivo lipoxygenase metabolism in neutrophils from patients with rheumatoid arthritis., J. Rheumatol.
Audouin et al., 2001, N-Aminoindoline derivatives as inhibitors of 5-lipoxygenase., Bioorg. Med. Chem. Lett.
Jeon et al., 2005, Nordihydroguaiaretic acid inhibits IFN-gamma-induced STAT tyrosine phosphorylation in rat brain astrocytes., Biochem. Biophys. Res. Commun.
Azadzoi et al., 2004, Alteration of urothelial-mediated tone in the ischemic bladder: role of eicosanoids., Neurourol. Urodyn.
West et al., 2004, The arachidonic acid 5-lipoxygenase inhibitor nordihydroguaiaretic acid inhibits tumor necrosis factor alpha activation of microglia and extends survival of G93A-SOD1 transgenic mice., J. Neurochem.
Lambert et al., 2001, Pharmacokinetic analysis by high-performance liquid chromatography of intravenous nordihydroguaiaretic acid in the mouse., J. Chromatogr. B Biomed. Sci. Appl.
Singh B et al., 2012, The hydroalcoholic extract of Cassia alata (Linn.) leaves and its major compound rhein exhibits antiallergic activity via mast cell stabilization and lipoxygenase inhibition., J Ethnopharmacol
MacCarrone M et al., 1999, Resveratrol prevents apoptosis in K562 cells by inhibiting lipoxygenase and cyclooxygenase activity., Eur J Biochem
Rolf MG et al., 2015, In vitro pharmacological profiling of R406 identifies molecular targets underlying the clinical effects of fostamatinib., Pharmacol Res Perspect

MESALAMINE ALOX5

Interaction Types & Directionality:

inhibitor (inhibitory)

Interaction Info:

Trial Name MAX-002

Novel drug target Established target

Mechanism of Interaction Arachidonate 5-lipoxygenase inhibitor

Publications:

Allgayer et al., 1984, Soybean lipoxygenase inhibition: studies with the sulphasalazine metabolites N-acetylaminosalicylic acid, 5-aminosalicylic acid and sulphapyridine., Eur. J. Clin. Pharmacol.

Nielsen et al., 1987, Inhibition of 5-lipoxygenase pathway of arachidonic acid metabolism in human neutrophils by sulfasalazine and 5-aminosalicylic acid., Dig. Dis. Sci.

Sircar et al., 1983, Inhibition of soybean lipoxygenase by sulfasalazine and 5-aminosalicylic acid: a possible mode of action in ulcerative colitis., Biochem. Pharmacol.

PF-4191834 ALOX5

Interaction Types & Directionality:

inhibitor (inhibitory)

Interaction Info:

Specific Action of the Ligand Inhibition

Endogenous Drug? False

Direct Interaction? True

Publications:
MECLOFENAMATE SODIUM ALOX5

Interaction Types & Directionality:

inhibitor (inhibitory)

Interaction Info:

Mechanism of Interaction Arachidonate 5-lipoxygenase inhibitor

Direct Interaction yes

Publications:
BALSALAZIDE DISODIUM ALOX5

Interaction Types & Directionality:

inhibitor (inhibitory)

Interaction Info:

Mechanism of Interaction Arachidonate 5-lipoxygenase inhibitor

Direct Interaction yes

Publications:
OLSALAZINE SODIUM ALOX5

Interaction Types & Directionality:

inhibitor (inhibitory)

Interaction Info:

Mechanism of Interaction Arachidonate 5-lipoxygenase inhibitor

Direct Interaction yes

Publications:
HYPERFORIN ALOX5

Interaction Types & Directionality:

inhibitor (inhibitory)

Interaction Info:

Publications:

Chen et al., 2002, TTD: Therapeutic Target Database., Nucleic Acids Res.

ZILEUTON ALOX5

Interaction Types & Directionality:

inhibitor (inhibitory)

Interaction Info:

Trial Name Zyflo

Novel drug target Established target

Mechanism of Interaction Arachidonate 5-lipoxygenase inhibitor

Publications:

Yamashita et al., 2000, Inhibition by troglitazone of the antigen-induced production of leukotrienes in immunoglobulin E-sensitized RBL-2H3 cells., Br. J. Pharmacol.

Wenzel, Leukotriene receptor antagonists and related compounds., Can. Respir. J.

Qian et al., 2001, Anti-inflammatory activities of LDP-392, a dual PAF receptor antagonist and 5-lipoxygenase inhibitor., Pharmacol. Res.

SULFASALAZINE ALOX5

Interaction Types & Directionality:

inhibitor (inhibitory)

Interaction Info:

Direct Interaction yes

Mechanism of Interaction Arachidonate 5-lipoxygenase inhibitor

Publications:

Allgayer et al., 1984, Soybean lipoxygenase inhibition: studies with the sulphasalazine metabolites N-acetylaminosalicylic acid, 5-aminosalicylic acid and sulphapyridine., Eur. J. Clin. Pharmacol.

Nielsen et al., 1987, Inhibition of 5-lipoxygenase pathway of arachidonic acid metabolism in human neutrophils by sulfasalazine and 5-aminosalicylic acid., Dig. Dis. Sci.

Sircar et al., 1983, Inhibition of soybean lipoxygenase by sulfasalazine and 5-aminosalicylic acid: a possible mode of action in ulcerative colitis., Biochem. Pharmacol.

DIETHYLCARBAMAZINE ALOX5

Interaction Types & Directionality:

inhibitor (inhibitory)

Interaction Info:

Publications:

Zunić et al., Inhibition of leukotriene formation by diethylcarbamazine modifies the acid-base balance in the rabbits with blast injuries of the lungs., Vojnosanit Pregl

Gross et al., 1991, Effects of some nonsteroidal anti-inflammatory agents on experimental radiation pneumonitis., Radiat. Res.

Bach et al., 1986, Inhibition of the leukotriene synthetase of rat basophil leukemia cells by diethylcarbamazine, and synergism between diethylcarbamazine and piriprost, a 5-lipoxygenase inhibitor., Biochem. Pharmacol.

MONTELUKAST ALOX5

Interaction Types & Directionality:

other/unknown

Interaction Info:

Publications:

Ramires et al., 2004, Novel inhibitory effect on 5-lipoxygenase activity by the anti-asthma drug montelukast., Biochem. Biophys. Res. Commun.

MINOCYCLINE ALOX5

Interaction Types & Directionality:

inhibitor (inhibitory)

Interaction Info:

Publications:

Chu et al., 2007, Minocycline inhibits 5-lipoxygenase activation and brain inflammation after focal cerebral ischemia in rats., Acta Pharmacol. Sin.

Song et al., 2006, Minocycline protects PC12 cells against NMDA-induced injury via inhibiting 5-lipoxygenase activation., Brain Res.

Song et al., 2004, Minocycline protects PC12 cells from ischemic-like injury and inhibits 5-lipoxygenase activation., Neuroreport

MECLOFENAMIC ACID ALOX5

Interaction Types & Directionality:

inhibitor (inhibitory)

Interaction Info:

Publications:

Yu et al., 1992, Inhibition of canine tracheal smooth muscle by mediators from cultured bronchial epithelial cells., Am. J. Physiol.

Boctor et al., 1986, Meclofenamate sodium is an inhibitor of both the 5-lipoxygenase and cyclooxygenase pathways of the arachidonic acid cascade in vitro., Prostaglandins Leukot Med

BALSALAZIDE ALOX5

Interaction Types & Directionality:

inhibitor (inhibitory)

Interaction Info:

Trial Name balsalazide disodium,Colazal, Giazo

Novel drug target Established target

Publications:

Rask-Madsen et al., 1992, 5-Lipoxygenase inhibitors for the treatment of inflammatory bowel disease., Agents Actions

Wiggins et al., 2009, Balsalazide: a novel 5-aminosalicylate prodrug for the treatment of active ulcerative colitis., Expert Opin Drug Metab Toxicol

MASOPROCOL ALOX5

Interaction Types & Directionality:

inhibitor (inhibitory)

Interaction Info:

Publications:

Audouin et al., 2001, N-Aminoindoline derivatives as inhibitors of 5-lipoxygenase., Bioorg. Med. Chem. Lett.

Chen et al., 2002, TTD: Therapeutic Target Database., Nucleic Acids Res.

Jeon et al., 2005, Nordihydroguaiaretic acid inhibits IFN-gamma-induced STAT tyrosine phosphorylation in rat brain astrocytes., Biochem. Biophys. Res. Commun.

DIACEREIN ALOX5

Interaction Types & Directionality:

inhibitor (inhibitory)

Interaction Info:

Publications:

Singh B et al., 2012, The hydroalcoholic extract of Cassia alata (Linn.) leaves and its major compound rhein exhibits antiallergic activity via mast cell stabilization and lipoxygenase inhibition., J Ethnopharmacol

FOSTAMATINIB ALOX5

Interaction Types & Directionality:

inhibitor (inhibitory)

Interaction Info:

Publications:

Rolf MG et al., 2015, In vitro pharmacological profiling of R406 identifies molecular targets underlying the clinical effects of fostamatinib., Pharmacol Res Perspect

RHEIN ALOX5

Interaction Types & Directionality:

inhibitor (inhibitory)

Interaction Info:

Publications:

Singh B et al., 2012, The hydroalcoholic extract of Cassia alata (Linn.) leaves and its major compound rhein exhibits antiallergic activity via mast cell stabilization and lipoxygenase inhibition., J Ethnopharmacol

MORNIFLUMATE ALOX5

Interaction Types & Directionality:

antagonist (inhibitory)

Interaction Info:

Publications:
ATRELEUTON ALOX5

Interaction Types & Directionality:

n/a

Interaction Info:

Trial Name VIA-2291

Novel drug target Established target

Publications:
CHEMBL416038 ALOX5

Interaction Types & Directionality:

n/a

Interaction Info:

Publications:

Wisastra R et al., 2013, Discovery of a novel activator of 5-lipoxygenase from an anacardic acid derived compound collection., Bioorg Med Chem
VITAMIN E ALOX5

Interaction Types & Directionality:

n/a

Interaction Info:

Publications:

Taccone-Gallucci et al., 2006, N-3 PUFAs reduce oxidative stress in ESRD patients on maintenance HD by inhibiting 5-lipoxygenase activity., Kidney Int.

LICOFELONE ALOX5

Interaction Types & Directionality:

n/a

Interaction Info:

Trial Name licofelone, ML3000

Novel drug target Established target

Publications:

Vidal et al., 2007, Licofelone, a balanced inhibitor of cyclooxygenase and 5-lipoxygenase, reduces inflammation in a rabbit model of atherosclerosis., J. Pharmacol. Exp. Ther.

Chen et al., 2002, TTD: Therapeutic Target Database., Nucleic Acids Res.

5-OXO-ETE ALOX5

Interaction Types & Directionality:

n/a

Interaction Info:

Publications:

Armstrong MM et al., 2014, Inhibitory and mechanistic investigations of oxo-lipids with human lipoxygenase isozymes., Bioorg Med Chem
ACACETIN ALOX5

Interaction Types & Directionality:

n/a

Interaction Info:

Publications:

Ribeiro D et al., 2014, Inhibition of LOX by flavonoids: a structure-activity relationship study., Eur J Med Chem
MELATONIN ALOX5

Interaction Types & Directionality:

n/a

Interaction Info:

Publications:

Manev et al., 1999, Primary cultures of rat cerebellar granule cells as a model to study neuronal 5-lipoxygenase and FLAP gene expression., Ann. N. Y. Acad. Sci.
CHEMBL502496 ALOX5

Interaction Types & Directionality:

n/a

Interaction Info:

Publications:

Wisastra R et al., 2013, Discovery of a novel activator of 5-lipoxygenase from an anacardic acid derived compound collection., Bioorg Med Chem
METHOTREXATE ALOX5

Interaction Types & Directionality:

n/a

Interaction Info:

Publications:

Hawkes et al., 1994, The effect of methotrexate on ex vivo lipoxygenase metabolism in neutrophils from patients with rheumatoid arthritis., J. Rheumatol.
6BIO ALOX5

Interaction Types & Directionality:

n/a

Interaction Info:

Publications:

Pergola C et al., 2014, Indirubin core structure of glycogen synthase kinase-3 inhibitors as novel chemotype for intervention with 5-lipoxygenase., J Med Chem
RESVERATROL ALOX5

Interaction Types & Directionality:

n/a

Interaction Info:

Publications:

MacCarrone M et al., 1999, Resveratrol prevents apoptosis in K562 cells by inhibiting lipoxygenase and cyclooxygenase activity., Eur J Biochem
TOCOPHEROL ACETATE ALOX5

Interaction Types & Directionality:

n/a

Interaction Info:

Publications:

Taccone-Gallucci et al., 2006, N-3 PUFAs reduce oxidative stress in ESRD patients on maintenance HD by inhibiting 5-lipoxygenase activity., Kidney Int.
(+)-ALPHA-TOCOPHERYL SUCCINATE ALOX5

Interaction Types & Directionality:

n/a

Interaction Info:

Publications:

Taccone-Gallucci et al., 2006, N-3 PUFAs reduce oxidative stress in ESRD patients on maintenance HD by inhibiting 5-lipoxygenase activity., Kidney Int.
TEPOXALIN ALOX5

Interaction Types & Directionality:

n/a

Interaction Info:

Publications:
TENIDAP ALOX5

Interaction Types & Directionality:

n/a

Interaction Info:

Publications:
RILOPIROX ALOX5

Interaction Types & Directionality:

n/a

Interaction Info:

Publications:
SILYBIN A ALOX5

Interaction Types & Directionality:

n/a

Interaction Info:

Publications:
TIPELUKAST ALOX5

Interaction Types & Directionality:

n/a

Interaction Info:

Publications:
DARBUFELONE ALOX5

Interaction Types & Directionality:

n/a

Interaction Info:

Publications:
CHEMBL73148 ALOX5

Interaction Types & Directionality:

n/a

Interaction Info:

Publications:

Ensembl: ENSG00000012779
- Version: 101_38
Alternate Names:

ALOX5 Ensembl Gene Name

Gene Info:

Gene Biotype PROTEIN_CODING

Publications:
TdgClinicalTrial: P09917
- Version: January-2014
Alternate Names:

ALOX5 Gene Symbol

Gene Info:

Target Class Enzymes

Target Subclass EC:1.13.11.34

Publications:
TEND: P09917
- Version: 01-August-2011
Alternate Names:

P09917 Uniprot Accession

240 Entrez Gene Id

ENSG00000012779 Ensembl Gene Id

Gene Info:

Target Main Class Enzymes

Target Subclass 1.13.11.34

Publications:
RussLampel: ENSG00000012779
- Version: 26-July-2011
Alternate Names:

ALOX5 Display Id

ARACHIDONATE 5-LIPOXYGENASE (EC 1.13.11.34) (5-LIPOXYGENASE) (5-LO). [SOURCE:UNIPROT/SWISSPROT;ACC:P09917] Description

ENSG00000012779 Ensembl Gene Id

Gene Info:

Human Readable Name DRUGGABLE GENOME

Gene Categories:

DRUGGABLE GENOME

Publications:
HopkinsGroom: P09917
- Version: 11-September-2012
Alternate Names:

LOX5_HUMAN Uniprot Id

P09917 Uniprot Accession

ALOX5 Uniprot Gene Name

Gene Info:

Human Readable Name DRUGGABLE GENOME

Interpro Acc IPR000907

Interpro Name Lipoxygenase

Gene Categories:

DRUGGABLE GENOME

Publications:
GuideToPharmacology: 240
- Version: 29-September-2020
Alternate Names:

435 HUGO Gene ID

435 HUGO Gene Symbol

arachidonate 5-lipoxygenase HUGO Gene Name

Gene Info:

GuideToPharmacology Gene Category Name Lipoxygenases

GuideToPharmacology Gene Category ID 271

Gene Categories:

ENZYME

Publications:

DrugBank: BE0000248

Version: 5.1.7

Alternate Names:

ALOX5 DrugBank Gene Name

P09917 UniProt Accession

240 Entrez Gene Id

Gene Info:

Publications:

Chen et al., 2002, TTD: Therapeutic Target Database., Nucleic Acids Res.

Lambert et al., 2001, Pharmacokinetic analysis by high-performance liquid chromatography of intravenous nordihydroguaiaretic acid in the mouse., J. Chromatogr. B Biomed. Sci. Appl.

Audouin et al., 2001, N-Aminoindoline derivatives as inhibitors of 5-lipoxygenase., Bioorg. Med. Chem. Lett.

TTD: Arachidonate 5-lipoxygenase

Version: 2020.06.01

Alternate Names:

5-LOX TTD Gene Abbreviation

T00140 TTD Target ID

Gene Info:

Publications:

Stanke-Labesque F et al., 2003, Inhibition of leukotriene synthesis with MK-886 prevents a rise in blood pressure and reduces noradrenaline-evoked contraction in L-NAME-treated rats., Br J Pharmacol

NCI: ALOX5

Version: 14-September-2017

Alternate Names:

Gene Info:

Publications:

Manev et al., 1999, Primary cultures of rat cerebellar granule cells as a model to study neuronal 5-lipoxygenase and FLAP gene expression., Ann. N. Y. Acad. Sci.

Jeon et al., 2005, Nordihydroguaiaretic acid inhibits IFN-gamma-induced STAT tyrosine phosphorylation in rat brain astrocytes., Biochem. Biophys. Res. Commun.

Ghosh, 2004, Rapid induction of apoptosis in prostate cancer cells by selenium: reversal by metabolites of arachidonate 5-lipoxygenase., Biochem. Biophys. Res. Commun.

DTC: ALOX5

Version: 02-September-2020

Alternate Names:

Gene Info:

Publications:

Schieferdecker S et al., 2015, Myxochelins target human 5-lipoxygenase., J Nat Prod

Karg EM et al., 2009, Structural optimization and biological evaluation of 2-substituted 5-hydroxyindole-3-carboxylates as potent inhibitors of human 5-lipoxygenase., J Med Chem

Pergola C et al., 2014, Indirubin core structure of glycogen synthase kinase-3 inhibitors as novel chemotype for intervention with 5-lipoxygenase., J Med Chem

ChemblInteractions: LOG5
- Version: chembl_23
Alternate Names:

LOG5 GENE_SYMBOL

ALOX5 GENE_SYMBOL

Arachidonate 5-lipoxygenase UNIPROT

Gene Info:

Publications:
HingoraniCasas: ENSG00000012779
- Version: 31-May-2017
Alternate Names:

ENSG00000012779 Gene Symbol

ALOX5 Ensembl Id

Gene Info:

Gene Categories:

DRUGGABLE GENOME

Publications:
PharmGKB: ALOX5
- Version: 18-August-2020
Alternate Names:

PA46 PharmGKB ID

Gene Info:

Publications:

Trial Name	MAX-002
Novel drug target	Established target
Mechanism of Interaction	Arachidonate 5-lipoxygenase inhibitor

Specific Action of the Ligand	Inhibition
Endogenous Drug?	False
Direct Interaction?	True

Mechanism of Interaction	Arachidonate 5-lipoxygenase inhibitor
Direct Interaction	yes

Trial Name	Zyflo
Novel drug target	Established target
Mechanism of Interaction	Arachidonate 5-lipoxygenase inhibitor

Trial Name	balsalazide disodium,Colazal, Giazo
Novel drug target	Established target

Trial Name	licofelone, ML3000
Novel drug target	Established target

P09917	Uniprot Accession
240	Entrez Gene Id
ENSG00000012779	Ensembl Gene Id

ALOX5	Display Id
ARACHIDONATE 5-LIPOXYGENASE (EC 1.13.11.34) (5-LIPOXYGENASE) (5-LO). [SOURCE:UNIPROT/SWISSPROT;ACC:P09917]	Description
ENSG00000012779	Ensembl Gene Id

LOX5_HUMAN	Uniprot Id
P09917	Uniprot Accession
ALOX5	Uniprot Gene Name

435	HUGO Gene ID
435	HUGO Gene Symbol
arachidonate 5-lipoxygenase	HUGO Gene Name

ALOX5	DrugBank Gene Name
P09917	UniProt Accession
240	Entrez Gene Id

LOG5	GENE_SYMBOL
ALOX5	GENE_SYMBOL
Arachidonate 5-lipoxygenase	UNIPROT

ALOX5 Gene Record

ALOX5 240 Druggable Genome

Alternate Names:

Gene Info:

Gene Categories: Category Details

Publications:

Interaction Types & Directionality: inhibitor (inhibitory)

Interaction Info: Trial Name MAX-002 Novel drug target Established target Mechanism of Interaction Arachidonate 5-lipoxygenase inhibitor

Interaction Types & Directionality: inhibitor (inhibitory)

Interaction Info: Specific Action of the Ligand Inhibition Endogenous Drug? False Direct Interaction? True

Publications:

Interaction Types & Directionality: inhibitor (inhibitory)

Interaction Info: Mechanism of Interaction Arachidonate 5-lipoxygenase inhibitor Direct Interaction yes

Publications:

Interaction Types & Directionality: inhibitor (inhibitory)

Interaction Info: Mechanism of Interaction Arachidonate 5-lipoxygenase inhibitor Direct Interaction yes

Publications:

Interaction Types & Directionality: inhibitor (inhibitory)

Interaction Info: Mechanism of Interaction Arachidonate 5-lipoxygenase inhibitor Direct Interaction yes

Publications:

Interaction Types & Directionality: inhibitor (inhibitory)

Interaction Info:

Publications: Chen et al., 2002, TTD: Therapeutic Target Database., Nucleic Acids Res.

Interaction Types & Directionality: inhibitor (inhibitory)

Interaction Info: Trial Name Zyflo Novel drug target Established target Mechanism of Interaction Arachidonate 5-lipoxygenase inhibitor

Interaction Types & Directionality: inhibitor (inhibitory)

Interaction Info: Direct Interaction yes Mechanism of Interaction Arachidonate 5-lipoxygenase inhibitor

Interaction Types & Directionality: inhibitor (inhibitory)

Interaction Info:

Interaction Types & Directionality: other/unknown

Interaction Info:

Publications: Ramires et al., 2004, Novel inhibitory effect on 5-lipoxygenase activity by the anti-asthma drug montelukast., Biochem. Biophys. Res. Commun.

Interaction Types & Directionality: inhibitor (inhibitory)

Interaction Info:

Interaction Types & Directionality: inhibitor (inhibitory)

Interaction Info:

Interaction Types & Directionality: inhibitor (inhibitory)

Interaction Info: Trial Name balsalazide disodium,Colazal, Giazo Novel drug target Established target

Publications: Rask-Madsen et al., 1992, 5-Lipoxygenase inhibitors for the treatment of inflammatory bowel disease., Agents Actions Wiggins et al., 2009, Balsalazide: a novel 5-aminosalicylate prodrug for the treatment of active ulcerative colitis., Expert Opin Drug Metab Toxicol

Interaction Types & Directionality: inhibitor (inhibitory)

Interaction Info:

Interaction Types & Directionality: inhibitor (inhibitory)

Interaction Info:

Publications: Singh B et al., 2012, The hydroalcoholic extract of Cassia alata (Linn.) leaves and its major compound rhein exhibits antiallergic activity via mast cell stabilization and lipoxygenase inhibition., J Ethnopharmacol

Interaction Types & Directionality: inhibitor (inhibitory)

Interaction Info:

Publications: Rolf MG et al., 2015, In vitro pharmacological profiling of R406 identifies molecular targets underlying the clinical effects of fostamatinib., Pharmacol Res Perspect

Interaction Types & Directionality: inhibitor (inhibitory)

Interaction Info:

Publications: Singh B et al., 2012, The hydroalcoholic extract of Cassia alata (Linn.) leaves and its major compound rhein exhibits antiallergic activity via mast cell stabilization and lipoxygenase inhibition., J Ethnopharmacol

Interaction Types & Directionality: antagonist (inhibitory)

Interaction Info:

Publications:

Interaction Types & Directionality: n/a

Interaction Info: Trial Name VIA-2291 Novel drug target Established target

Publications:

Interaction Types & Directionality: n/a

Interaction Info:

Publications: Wisastra R et al., 2013, Discovery of a novel activator of 5-lipoxygenase from an anacardic acid derived compound collection., Bioorg Med Chem

Interaction Types & Directionality: n/a

Interaction Info:

Publications: Taccone-Gallucci et al., 2006, N-3 PUFAs reduce oxidative stress in ESRD patients on maintenance HD by inhibiting 5-lipoxygenase activity., Kidney Int.

Interaction Types & Directionality: n/a

Interaction Info: Trial Name licofelone, ML3000 Novel drug target Established target

Publications: Vidal et al., 2007, Licofelone, a balanced inhibitor of cyclooxygenase and 5-lipoxygenase, reduces inflammation in a rabbit model of atherosclerosis., J. Pharmacol. Exp. Ther. Chen et al., 2002, TTD: Therapeutic Target Database., Nucleic Acids Res.

Interaction Types & Directionality: n/a

Interaction Info:

Publications: Armstrong MM et al., 2014, Inhibitory and mechanistic investigations of oxo-lipids with human lipoxygenase isozymes., Bioorg Med Chem

Interaction Types & Directionality: n/a

Interaction Info:

Publications: Ribeiro D et al., 2014, Inhibition of LOX by flavonoids: a structure-activity relationship study., Eur J Med Chem

Interaction Types & Directionality: n/a

Interaction Info:

Publications: Manev et al., 1999, Primary cultures of rat cerebellar granule cells as a model to study neuronal 5-lipoxygenase and FLAP gene expression., Ann. N. Y. Acad. Sci.

Interaction Types & Directionality: n/a

Interaction Info:

Publications: Wisastra R et al., 2013, Discovery of a novel activator of 5-lipoxygenase from an anacardic acid derived compound collection., Bioorg Med Chem

Interaction Types & Directionality: n/a

Interaction Info:

Publications: Hawkes et al., 1994, The effect of methotrexate on ex vivo lipoxygenase metabolism in neutrophils from patients with rheumatoid arthritis., J. Rheumatol.

Interaction Types & Directionality:

inhibitor (inhibitory)

Interaction Info:

Trial Name MAX-002

Novel drug target Established target

Mechanism of Interaction Arachidonate 5-lipoxygenase inhibitor

Interaction Types & Directionality:

inhibitor (inhibitory)

Interaction Info:

Specific Action of the Ligand Inhibition

Endogenous Drug? False

Direct Interaction? True

Interaction Types & Directionality:

inhibitor (inhibitory)

Interaction Info:

Mechanism of Interaction Arachidonate 5-lipoxygenase inhibitor

Direct Interaction yes

Interaction Types & Directionality:

inhibitor (inhibitory)

Interaction Info:

Mechanism of Interaction Arachidonate 5-lipoxygenase inhibitor

Direct Interaction yes

Interaction Types & Directionality:

inhibitor (inhibitory)

Interaction Info:

Mechanism of Interaction Arachidonate 5-lipoxygenase inhibitor

Direct Interaction yes

Interaction Types & Directionality:

inhibitor (inhibitory)

Publications:

Chen et al., 2002, TTD: Therapeutic Target Database., Nucleic Acids Res.

Interaction Types & Directionality:

inhibitor (inhibitory)

Interaction Info:

Trial Name Zyflo

Novel drug target Established target

Mechanism of Interaction Arachidonate 5-lipoxygenase inhibitor

Interaction Types & Directionality:

inhibitor (inhibitory)

Interaction Info:

Direct Interaction yes

Mechanism of Interaction Arachidonate 5-lipoxygenase inhibitor

Interaction Types & Directionality:

inhibitor (inhibitory)

Interaction Types & Directionality:

other/unknown

Publications:

Ramires et al., 2004, Novel inhibitory effect on 5-lipoxygenase activity by the anti-asthma drug montelukast., Biochem. Biophys. Res. Commun.

Interaction Types & Directionality:

inhibitor (inhibitory)

Interaction Types & Directionality:

inhibitor (inhibitory)

Interaction Types & Directionality:

inhibitor (inhibitory)

Interaction Info:

Trial Name balsalazide disodium,Colazal, Giazo

Novel drug target Established target

Publications:

Rask-Madsen et al., 1992, 5-Lipoxygenase inhibitors for the treatment of inflammatory bowel disease., Agents Actions

Wiggins et al., 2009, Balsalazide: a novel 5-aminosalicylate prodrug for the treatment of active ulcerative colitis., Expert Opin Drug Metab Toxicol

Interaction Types & Directionality:

inhibitor (inhibitory)

Interaction Types & Directionality:

inhibitor (inhibitory)

Publications:

Singh B et al., 2012, The hydroalcoholic extract of Cassia alata (Linn.) leaves and its major compound rhein exhibits antiallergic activity via mast cell stabilization and lipoxygenase inhibition., J Ethnopharmacol

Interaction Types & Directionality:

inhibitor (inhibitory)

Publications:

Rolf MG et al., 2015, In vitro pharmacological profiling of R406 identifies molecular targets underlying the clinical effects of fostamatinib., Pharmacol Res Perspect

Interaction Types & Directionality:

inhibitor (inhibitory)

Publications:

Singh B et al., 2012, The hydroalcoholic extract of Cassia alata (Linn.) leaves and its major compound rhein exhibits antiallergic activity via mast cell stabilization and lipoxygenase inhibition., J Ethnopharmacol

Interaction Types & Directionality:

antagonist (inhibitory)

Interaction Types & Directionality:

n/a

Interaction Info:

Trial Name VIA-2291

Novel drug target Established target

Interaction Types & Directionality:

n/a

Publications:

Wisastra R et al., 2013, Discovery of a novel activator of 5-lipoxygenase from an anacardic acid derived compound collection., Bioorg Med Chem

Interaction Types & Directionality:

n/a

Publications:

Taccone-Gallucci et al., 2006, N-3 PUFAs reduce oxidative stress in ESRD patients on maintenance HD by inhibiting 5-lipoxygenase activity., Kidney Int.

Interaction Types & Directionality:

n/a

Interaction Info:

Trial Name licofelone, ML3000

Novel drug target Established target

Publications:

Vidal et al., 2007, Licofelone, a balanced inhibitor of cyclooxygenase and 5-lipoxygenase, reduces inflammation in a rabbit model of atherosclerosis., J. Pharmacol. Exp. Ther.

Chen et al., 2002, TTD: Therapeutic Target Database., Nucleic Acids Res.

Interaction Types & Directionality:

n/a

Publications:

Armstrong MM et al., 2014, Inhibitory and mechanistic investigations of oxo-lipids with human lipoxygenase isozymes., Bioorg Med Chem

Interaction Types & Directionality:

n/a

Publications:

Ribeiro D et al., 2014, Inhibition of LOX by flavonoids: a structure-activity relationship study., Eur J Med Chem

Interaction Types & Directionality:

n/a

Publications:

Manev et al., 1999, Primary cultures of rat cerebellar granule cells as a model to study neuronal 5-lipoxygenase and FLAP gene expression., Ann. N. Y. Acad. Sci.

Interaction Types & Directionality:

n/a

Publications:

Wisastra R et al., 2013, Discovery of a novel activator of 5-lipoxygenase from an anacardic acid derived compound collection., Bioorg Med Chem

Interaction Types & Directionality:

n/a

Publications:

Hawkes et al., 1994, The effect of methotrexate on ex vivo lipoxygenase metabolism in neutrophils from patients with rheumatoid arthritis., J. Rheumatol.

Interaction Types & Directionality:

n/a

Publications:

Pergola C et al., 2014, Indirubin core structure of glycogen synthase kinase-3 inhibitors as novel chemotype for intervention with 5-lipoxygenase., J Med Chem

Interaction Types & Directionality:

n/a

Publications:

MacCarrone M et al., 1999, Resveratrol prevents apoptosis in K562 cells by inhibiting lipoxygenase and cyclooxygenase activity., Eur J Biochem

Interaction Types & Directionality:

n/a

Publications:

Taccone-Gallucci et al., 2006, N-3 PUFAs reduce oxidative stress in ESRD patients on maintenance HD by inhibiting 5-lipoxygenase activity., Kidney Int.

Interaction Types & Directionality:

n/a

Publications:

Taccone-Gallucci et al., 2006, N-3 PUFAs reduce oxidative stress in ESRD patients on maintenance HD by inhibiting 5-lipoxygenase activity., Kidney Int.

Interaction Types & Directionality:

n/a

Interaction Types & Directionality:

n/a

Interaction Types & Directionality:

n/a

Interaction Types & Directionality:

n/a

Interaction Types & Directionality:

n/a